We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights
GCVRZ

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

Back to rankings

103 hedge funds and large institutions have $73.1M invested in Sanofi Contingent Value Rights in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

3% less funds holding

Funds holding: 106 → 103 (-3)

9% less capital invested

Capital invested by funds: $80.4M → $73.1M (-$7.35M)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

39% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 18

Holders
103
Holders Change
-3
Holders Change %
-2.83%
% of All Funds
2.3%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
8
Increased
11
Reduced
18
Closed
11
Calls
$15.1M
Puts
–
Net Calls
+$15.1M
Net Calls Change
+$15.1M

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonehill Capital Management
New York
+$2.73M
2
HCM
Highbridge Capital Management
New York
+$295K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$65.3K
4
Goldman Sachs
Goldman Sachs
New York
+$45.5K
5
TSS
Two Sigma Securities
New York
+$15.1K

Top Sellers

Rank Fund Capital Flow
1
BMO
Beck Mack & Oliver
New York
-$174K
2
CI
Cowen Inc
New York
-$30K
3
Citadel Advisors
Citadel Advisors
Florida
-$23.1K
4
MCM
Mainstay Capital Management
Michigan
-$14K
5
CS
Credit Suisse
Switzerland
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonehill Capital Management
New York
$23.4M +$2.73M +5,496,160 +13%
EM
2
Elliott Management
New York
$9.81M – – –
MCM
3
Mason Capital Management
New York
$7.03M – – –
TGHSA
4
TPG Group Holdings (SBS) Advisors
Texas
$6.83M – – –
BCM
5
Brigade Capital Management
New York
$5.89M – – –
HCM
6
Highbridge Capital Management
New York
$4.56M +$295K +593,486 +7%
WA
7
Whitebox Advisors
Minnesota
$3.34M – – –
FCM
8
Farallon Capital Management
California
$3.28M – – –
NGA
9
New Generation Advisors
Massachusetts
$2.05M – – –
MFP
10
Michael F. Price
$1.72M – – –
AMH
11
Apollo Management Holdings
New York
$835K – – –
CL
12
CSS LLC
Illinois
$794K -$4.17K -8,403 -0.5%
UOC
13
UBS O'Connor
Illinois
$558K – – –
SAM
14
Silverback Asset Management
North Carolina
$378K – – –
GF
15
Gabelli Funds
New York
$331K – – –
Goldman Sachs
16
Goldman Sachs
New York
$299K +$45.5K +91,503 +17%
Adage Capital Partners
17
Adage Capital Partners
Massachusetts
$295K – – –
DAM
18
DLD Asset Management
New York
$282K +$248 +500 +0.1%
WC
19
Wexford Capital
Florida
$240K – – –
TL
20
TowerView LLC
New York
$230K – – –
TA
21
Teton Advisors
New York
$192K – – –
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$123K +$65.3K +131,437 +105%
BRF
23
B. Riley Financial
California
$101K +$5.66K +11,388 +6%
Wells Fargo
24
Wells Fargo
California
$75K -$1.76K -3,538 -2%
YCM
25
Yakira Capital Management
Connecticut
$74K – – –
1
2 3 4

GCVRZ Hedge Fund Activity: Q4 2018 in Review

103 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q4 2018, worth a combined $73.1M — down 9.1% from $80.4M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of GCVRZ and 8 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 11 added.

The largest buyer was Stonehill Capital Management, adding an estimated $2.73M. The largest seller was Beck Mack & Oliver, exiting entirely with an estimated $174K sold.

  • 103 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q4 2018, down from 106 in Q3 2018.
  • Funds reported $73.1M of Sanofi Contingent Value Rights stock for Q4 2018, down 9.1% quarter-over-quarter.
  • 8 funds opened new Sanofi Contingent Value Rights positions in Q4 2018 and 11 closed out, a net change of -3 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q4 2018 was Stonehill Capital Management, an estimated $2.73M added.
  • The largest Sanofi Contingent Value Rights seller in Q4 2018 was Beck Mack & Oliver, an estimated $174K sold.

Based on aggregated 13F filings for Q4 2018.